Comparison · NCT03181503-sae
Nemolizumab 0.5 mg/kg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nemolizumab 0.5 mg/kg vs Placebo: serious adverse events. Trial comparisons, record NCT03181503-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03181503-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.118 | 0.0467 | 0.266 | wilson | |
| Risk in group 2 | 0.0833 | 0.0287 | 0.218 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0343 | -0.118 | 0.193 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.41 | 0.341 | 5.85 | log | |
| Odds ratio, group 1 over group 2 | 1.47 | 0.303 | 7.1 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Nemolizumab 0.5 mg/kg than on Placebo | 29.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nemolizumab 0.5 mg/kg | Participants received 3 subcutaneous injections of nemolizumab 0.5 mg/kg Q4W for 12 weeks (Baseline, Week 4 and Week 8). Participants were further followed up for 6 weeks. | 4 | 34 | EG001 |
| Group 2 | Placebo | Participants received 3 subcutaneous injections of placebo (matched to nemolizumab) Q4W for 12 weeks (Baseline, Week 4 and Week 8). Participants were further followed up for 6 weeks. | 3 | 36 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 18 Weeks
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Nemolizumab in PN
- NCT number
- NCT03181503
- Phases
- PHASE2
- Conditions
- Prurigo Nodularis
- Interventions
- CD14152 Dose A, CD14152 placebo
- Lead sponsor
- Galderma R&D
- Results first posted
- 2020-02-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03181503?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03181503-sae